Showing results (301-310 of 305) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 305 results.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 31